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The successful treatment of psoriasis with folic acid antagonists during the past 25 years 
has led to extensive research in the areas of cytokinetics and chemotherapy. In this paper we 
shall review selected aspects of these topics relevant to the treatment of psoriasis. The 
effectiveness of methotrexate treatment of psoriasis can be related to both the hyperprolifer-
ative cytokinetics of psoriasis and an increased biochemical sensitivity of psoriatic epidermal 
cells to this drug. 
Future research goals in chemotherapy of psoriasis include (a) optimizing drug schedules 
for available drugs; (b) identifying other susceptible biochemical points of selective drug 
attack; (c) identifying secondary advantages in order to facilitate selective drug action in 
psoriasis, such as ultraviolet light therapy in combination with a systemic drug; and (d) 
developing topically effective chemotherapeutic agents. Approaches. to research on topical 
therapy are reviewed with specific reference to animal testing models for psoriasis and 
percutaneous penetration of topically applied agents. 
The story of the chemotherapy of psoriasis began 
a quarter of a century ago with the first reported 
use of aminopterin for psoriasis [1 J. Subsequent 
reports describing various aspects of treatment 
with aminopterin and its successor, methotrexate 
(MTX), have detailed the growing effectiveness of 
different drug schedules as well as concerns with 
toxicity. MTX has remained the principal-form of 
systemic chemotherapy of severe psoriasis. 
As a by-product of the success of MTX therapy , 
research on the basic biologic and biochemical 
properties of psoriasis has been greatly stimulated. 
Psoriatic epidermis was noted to have an ex-
tremely high number of mitoses [2] and a rapid 
turnover using isotopic measuring techniques [3, 
4]. The 2-day transit time of cells through the 
viable psoriatic differentiated cell compartment-
compared to an approximate 2-week period in 
normal skin [4 J-suggested a faster rate of cell 
reproduction in the psoriatic basal (proliferative 
cell) layers. Autoradiographic techniques deter-
mined the psoriatic cell cycle to be 37.5 hr, 
compared to 457 hr for normal cells [5 J. 
Recent interest in the cytokinetics of psoriasis 
has focused on the physiologic controls of cell 
proliferation and on application to chemotherapy. 
The current theories concerning cyclic AMP-GMP 
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control of cell division relate directly to the hyper-
proliferative state of psoriatic epidermal cells. 
Experiments with human epidermal cell prolifera-
tion have shown that the cell cycle kinetics of 
normal and psoriatic skin grown in vitro become 
similar [6); the normal epidermal cell kinetics 
speeds up to equal that of the psoriatic cell. What, 
then, is the true native state of epidermal cells? Is 
the cell stimulated to proliferate rapidly in psoria-
sis or inhibited by controls in normal epidermis to 
proliferate slowly? The obvious interplay of bio-
chemical signals regulating cell proliferation is 
incompletely understood. 
Most cancer chemotherapeutic drugs either act 
on cells in a specific phase of the cell cycle or affect 
cells regardless of their temporal location in the 
cycle (nonspecific cell cycle drugs). Such alkylat-
ing agents as nitrogen mustard are among the 
latter. MTX, hydroxyurea, and cytosine arabino-
side are examples of S (DNA synthesis) phase 
cycle-specific drugs. These drugs affect cells only 
when they are in the S phase portion of the cycle. 
Similarly, colchicine and vincristine are specific 
cell cycle poisons for the M (mitotic) phase. This 
information can be used to program chemotherapy 
schedules using one drug or a combination for 
selected diseases based on their cytokinetics. In 
this manner a pharmacologically rational schedule 
for psoriasis was developed utilizing the cell cycle 
value of 37 hr and an S phase-specific drug, MTX 
[7]. Administration of three doses of the drug at 
12-hr intervals exposes all psoriatic cells to the 
toxic effects of MTX as they pass through the S 
phase. The triple-dose therapy schedule, requiring 
a smaller dose of MTX per week than did previous 
schedules, is now used for over 60 % of 
MTX-treated patients [8 J. 
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The vast clinical experience in this area shows 
that careful use of MTX to clear psoriasis has little 
effect on other proliferative tissues; normal skin, 
hair, and nail growth are not significantly altered, 
and bone marrow elements, the gastrointestinal 
tract, and buccal mucosa are subject to minimal 
side effects at relatively higher doses of MTX. 
There are two current explanations for the selec-
tive advantage of psoriasis over other normal 
proliferating tissues: 
1. Cell cycle kinetics advantage. Twenty-three 
percent of psoriatic epidermal cells are in the S 
phase at any moment compared to only 4% in 
normal skin. Thus, a single dose ofMTX acting on 
S phase cells will, at a given time, affect 6 times as 
many psoriatic cells as normal proliferating epi-
dermal cells. If the dose is continued over 36 hr, 
100% of the psoriatic cells will be affected whereas 
only about 9% of normal cells will enter the 
susceptible S phase during this time period (4 % 
new S phase cells in normal epidermis every 16 hr). 
Thus, for tissues proliferating more slowly than 
psoriatic epidermis, i.e., normal skin, bone mar-
row, and nail, a differential pharmacologic effect 
can be readily appreciated. 
2. Differential biochemical sensitivity of psoria-
sis . The inhibition of DNA synthesis in psoriatic 
epidermal cells is quantitatively greater than that 
in normal skin for given doses of MTX [9]. 
Psoriatic cells also demonstrate a selective sensi-
tivity to MTX as measured by mitotic activity and 
the production of "damaged cells" [10]. Explana-
tion of this selective sensitivity to MTX is still 
unknown and is discussed elsewhere [11]. 
CHEMOTHERAPY OF PSORIASIS 
Systemic therapy of severe psoriasis with various 
drugs has been evaluated in many studies. The 
only drug besides MTX approved by the FDA for 
treatment of psoriasis is azaribine. Other drugs 
frequently used or being tested include hydroxy-
urea and mycophenolic acid, but because of their 
side effects these drugs are unacceptable. 
Research goals for the chemotherapy of psoriasis 
include the following: 
1. Development of optimal schedules for the 
available systemic drugs. Whereas much valuable 
experience has been gained by changing MTX 
dosage schedules, - few data are available on 
different schedules for hydroxyurea and azaribine 
relating their specific pharmacology to the cellular 
kinetics of psoriasis. 
2. Identification of other susceptible biochemi-
l' al points for drug attack that will be selective for 
) soriasis while minimizing toxicity in normal tis-
iues. 
3. Identification of drugs for selective action on 
psoriatic tissue because of secondary advantages. 
Two examples of this are phototherapy with psora-
len and ultraviolet light (PUVA), and myco-
phenolic acid. PUVA therapy is active only in skin 
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(and eyes) by virtue of the limitations of light 
penetration to other organs of the body. Although 
the drug is systemically distributed, toxicity due to 
the combination of light and drug should not be 
found elsewhere in the body. Existing data suggest 
that psoralens alone , in the recommended dosages, 
are without side effects. Mycophenolic acid is an 
example of a potentially unique drug principle for 
use in skin diseases. Systemically administered 
mycophenolic acid is rapidly converted by the liver 
to an inactive glucuronide, which cannot penetrate 
cell membranes. Theoretically, only epidermal 
tissues and others containing a glucuronidase can 
hydrolyze the conjugated compound back to its 
free, active form [12]. 
4. Development of topical chemotherapeutic 
agents permitting the use of relatively potent 
cytotoxic drugs with minimal risk of systemic side 
effects. The remainder of this paper will deal with 
selected aspects of topical chemotherapy. 
Since psoriasis is a hyperproliferative disease 
which responds to drugs that affect proliferating 
cell populations, it is reasonable to assume that 
these drugs are acting directly on the skin rather 
than at a distant site. Clinically, nitrogen mustard, 
thiotepa [13], and nitrosourea [14] have been 
shown to clear psoriasis topically, providing evi-
dence of mechanisms for local therapeutic control. 
Injected intradermally into psoriatic skin, MTX 
will produce the same inhibition of DNA synthesis 
and mitoses that occurs after systemic administra-
tion, suggesting that the drug works locally (al-
though such local infusion of MTX does not clear 
psoriasis). In an experimental animal system, 
healing of skin wounds can be prevented by topical 
administration of MTX, presumably by stopping 
cell proliferation. Regional perfusion of MTX pro-
duces cytotoxic effects directly on tumors. For all 
these reasons, drugs like MTX and other chemo-
therapeutic agents should act directly on a hyper-
proliferative disease like psoriasis. 
THE ENIGMA OF THE INEFFECTIVENESS OF TOPICAL 
MTX 
Several factors may explain the topical ineffec-
tiveness of MTX: (a) lack of percutaneous penetra-
tion; (b) drug inactivation in skin during penetra-
tion; (c) a major effect at a distal site; and (d) the 
necessity for conversion elsewhere into an active 
compound. Brief discussion of current investiga-
tion into these possibilities follows. 
(a) Studies show that MTX preparations in an 
aqueous vehicle produce negligible penetration of 
the stratum corneum and thus the drug is not 
delivered to the proliferative epidermal cells where 
it is thought to act. It is assumed that if the drug 
penetrates the stratum corneum it will penetrate 
the epidermal cells. This appears to contribute to 
the lack of topical effect. 
(b) Incubation of MTX with skin shows no 
evidence of significant drug alteration or inactiva-
tion (McCullough and Weinstein, unpublished 
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observations). Similar findings have been observed 
when the drug is given to animals or patients 
systemically. 
(c) If MTX acts systemically at a site distant 
from the psoriatic skin , two mechanisms are sug-
gested. First, psoriasis might be controlled by a 
different organ susceptible to MTX, such as the 
liver. Second, MTX might prevent the production 
of an unknown circulating compound such as a 
reduced folate coenzyme necessary to maintain the 
activity of the psoriatic lesion. No evidence is 
currently available to support these possibilities. 
(d) There is no evidence that MTX is converted 
into a more active metabolite at a distal site. 
DEVELOPMENT OF TOPICAL ANTIPSORIATIC DRUGS 
A research program to develop topical anti-
psoriatic drugs has many biochemical, pharmaco-
logic, and clinical experimental aspects. After 
selecting potentially valuable compounds from 
biochemical predictive assays, it would be advan-
tageous to test them on experimental animals . 
Unlike animal leukemias or tumors, an experimen-
tal animal model system has never been developed 
for psoriasis. In recent years , much effort has been 
invested in creating psoriasis-testing models , sev-
eral of which will be reviewed here . 
The mouse vaginal mitotic screen was developed 
by Van Scott et al [15]. Vaginal epithelium stimu-
lated by estrogen to hyperproliferation is exposed 
to drugs by intravaginal application . The vaginal 
and neighboring rectal epithelia are examined 
histologically for mitotic counts. Inhibition of mi-
toses in the vaginal epithelium with no effect on 
the rectal epithelium indicates a direct local drug 
effect on the proliferative vaginal cells. A normal 
mitotic count in the rectum is the simultaneous 
control ruling out systemic absorption as the cause 
of the vaginal mitotic inhibition. This simple assay 
is useful for rapid screening of many drugs. 
The mouse vaginal assay has been modified in 
our laboratory to test the effect of drugs on the 
inhibition of DNA, RNA, and protein synthesis 
[16]. After the drugs are introduced intravaginally, 
the animals are injected intra peritoneally wi~h 
isotopic precursors, [3H ]thymidine or [3H ]deox-
yuridine for DNA synthesis ; [3H]uridine for RNA 
synthesis ; or [3H ]leucine for protein synthesis. 
Vaginal-rectal bloc specimens are examined auto-
radiographically for incorporation of these precur-
sors as a measure of their respective inhibition by 
each drug after "local" drug administration . 
Another simple assay system studied in our 
laboratories involves the production of discrete 
cutaneous wounds with punch biopsies. Healing of 
these wounds requires epidermal regeneration, 
which might be halted or retarded by topical 
application of effective agents. This assay has been 
used in both human [17] and nonhuman skin to 
test the local effects of drugs on epidermal regener-
ation as a model for psoriasis. 
An assay by duVivier and Stoughton uses ul -
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traviolet light-stimulated hyperproliferative epi-
dermis from hairless mice [18]. Changes in the 
hyperproliferative process brought about (effected) 
by the drugs are measured by mitotic counts, 
thymidine labeling indices, and/or quantitative 
measures of DNA synthesis. Topical local effects 
can be separated from systemic effects. 
One model for a psoriasiform disease is the 
essential fatty acid (EF A) -deficient rat [19]. The 
proliferative aspects of this model are scaling 
hyperkeratotic skin with rapid cell .proliferation 
(unpublished observations). Comparison of normal 
and EFA-deficient rat skin demonstrates a differ-
ence in epidermal thickness and respective label-
ing indices of 4 and 25% (Fig.). The transit time of 
thymidine-labeled cells from the basal to the granu-
lar layer is 2 days. These numbers are comparable 
to normal and psoriatic skin, suggesting a biologic 
similarity to the clinical disease. 
Another animal model with great potential for 
studying psoriasis and many other diseases-par-
ticularly tumors-is the athymic " nude" mouse , 
which is able to continue the growth of heterolo-
gously transplanted tissue . Krueger et al reported 
graft survival periods of 2 to 3 months in the first 
studies of psoriasis transplants in nude mice [20]. 
At this writing, only histologic criteria have been 
used to show that the graft still appears as the 
original human tissue . Briggaman and Weinstein 
are investigating the cellular kinetics of lamellar 
FIG. Autoradiographs of [3H]thymidine labeling of (A) 
normal rat skin, and (B) EF A-deficient rat skin ( x 160) . 
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ichthyosis in the same animal model. The experi-
mental thymidine transit time in the graft site is 
similar to that found in patients with lamellar ich-
thyosis . 
PERCUTANEOUS PENETRATION AND TOPICAL 
THERAPY 
Another problem to be considered in the rational 
development of a topically effective antipsoriatic 
drug involves percutaneous penetration. The low 
permeability of the skin acts as a selective barrier 
to the penetration of some topical medications. 
Consideration must therefore be given to the 
inherent ability of a given drug to penetrate this 
barrier as well as to the selection of the appropriate 
vehicle to optimize topical penetration. In vitro 
test systems measuring drug penetration through 
excised human skin are useful for studying the 
percutaneous penetration of topical chemothera-
peutic agents . We have used this technique to 
study the factors affecting human percutaneous 
penetration of MTX and its analogues in vitro [21 J. 
We found no percutaneous penetration of 
[3H]MTX from an applied aqueous solution (less 
than 0.005% of the applied drug dose). However, 
[3H ]MTX found in the epidermis was localized to 
the outermost layers of the stratum corneum. 
These results suggest that one explanation for the 
clinical ineffectiveness of topical MTX in psoriasis 
is the lack of sufficient penetration into or through 
the viable epidermis. One way to enhance the 
percutaneous penetration of a drug is to increase 
the lipophilic character of the molecule. We found 
that both the epidermal concentration and percu-
taneous penetration were enhanced by increasing 
the lipid solubility of MTX through chlorination 
and/or esterification of the parent molecule (Tab.). 
Another approach involves alteration of the 
vehicle which plays a critical role in the release and 
partitioning of the drug to the skin surface. In our 
study, the in vitro percutaneous penetration of 
TABLE. Percutaneous penetration of various folic acid 
antagonists through human skin in vitro 
Ratio of penetration of drug/ 
MTX [21] 
Druga Partition 
Epidermis Saline coefficient 
ratio [21 J" 
Methotrexate 1.0 1.0 1 
Methotrexa te- 14.53 1. 22 1,150 
dimethylester 
Dichloromethotrexate 1.14 1.27 10 
Dichloromethotrexate- 14.87 3.04 1,632 
dimethylester 
a .05 % soln of drug applied to epidermal chamber of a 
glass diffusion cell and incubated for 20 hr at 28°C. Drug 
concentration in the epidermis and in the lower dermal 
saline reservoir was determined by dihydrofolate reduc-
tase assay. 
b Ratio of partition coefficient of drug/MTX in n-
octanol-sodium phosphate buffer. 
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MTX was enhanced approximately 140-fold by 
incorporating it into the vehicle n-decylmethyl-
sulfoxide. These investigations of percutaneous 
penetration will aid in selecting and compounding 
other potential topical drugs and are essential to 
the understanding of any lack of topical activity . 
The empirical approach to drug selection and 
patient testing has been widely used with varying 
degrees of success. Compared to the scientific 
approach, it must bear the burden of local and 
federal regulatory agencies governing the criteria 
for human testing. There is now a strong effort to 
combine the scientific and empirical approaches in 
screening topical chemotherapeutic drugs for 
treatment of psoriasis. The National Institute of 
Arthritis , Metabolism, and Digestive Diseases has 
recently awarded a contract to the University of 
Miami Department of Dermatology to organize a 
multi-institutional study of selected chemothera-
peutic agents for the topical therapy of psoriasis, a 
clinical study that may lead to a better under-
standing of safe and effective topical treatment. 
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